Oct. 24 at 4:03 AM
M&A Potential in 2025
Based on recent developments (as of October 23, 2025), both
$MNKD (MannKind Corporation) and
$ABEO (Abeona Therapeutics) exhibit strong M&A potential in the biotech sector. The industry is seeing accelerated deal activity—Q3 2025 M&A volume hit
$30.8B, up 25% YoY—driven by Big Pharma's push into rare diseases, inhaled therapies, and gene editing amid deregulation. MNKD's recent acquisition positions it as a consolidator, while ABEO's undervalued gene therapy pipeline makes it an attractive bolt-on target.
Analysts (e.g., Zacks, HC Wainwright) rate both as "Strong Buy," with M&A as a top catalyst for 50-100% upside.
- Source: Grok
